CN107440103A - A kind of respiratory disease tailored version clinical nutrition formula and preparation method thereof - Google Patents
A kind of respiratory disease tailored version clinical nutrition formula and preparation method thereof Download PDFInfo
- Publication number
- CN107440103A CN107440103A CN201710731367.4A CN201710731367A CN107440103A CN 107440103 A CN107440103 A CN 107440103A CN 201710731367 A CN201710731367 A CN 201710731367A CN 107440103 A CN107440103 A CN 107440103A
- Authority
- CN
- China
- Prior art keywords
- powder
- respiratory disease
- vitamin
- clinical nutrition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 44
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 43
- 230000035764 nutrition Effects 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000009472 formulation Methods 0.000 title abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 113
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 235000015097 nutrients Nutrition 0.000 claims abstract description 39
- 229940088594 vitamin Drugs 0.000 claims abstract description 35
- 229930003231 vitamin Natural products 0.000 claims abstract description 35
- 235000013343 vitamin Nutrition 0.000 claims abstract description 35
- 239000011782 vitamin Substances 0.000 claims abstract description 35
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 230000035622 drinking Effects 0.000 claims abstract description 23
- 235000008216 herbs Nutrition 0.000 claims abstract description 23
- 230000010354 integration Effects 0.000 claims abstract description 23
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 235000012054 meals Nutrition 0.000 claims abstract description 15
- 239000011573 trace mineral Substances 0.000 claims abstract description 13
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 13
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 6
- 238000001694 spray drying Methods 0.000 claims abstract description 6
- 238000003809 water extraction Methods 0.000 claims abstract description 5
- 239000003925 fat Substances 0.000 claims abstract description 4
- 235000013350 formula milk Nutrition 0.000 claims description 28
- 235000019197 fats Nutrition 0.000 claims description 26
- 239000002994 raw material Substances 0.000 claims description 20
- 235000004347 Perilla Nutrition 0.000 claims description 18
- 244000124853 Perilla frutescens Species 0.000 claims description 18
- 235000018102 proteins Nutrition 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 16
- 235000014633 carbohydrates Nutrition 0.000 claims description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- 241000234435 Lilium Species 0.000 claims description 13
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 12
- 240000003582 Platycodon grandiflorus Species 0.000 claims description 12
- 244000246386 Mentha pulegium Species 0.000 claims description 11
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 11
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 11
- 244000185386 Thladiantha grosvenorii Species 0.000 claims description 11
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 239000000835 fiber Substances 0.000 claims description 11
- 235000001050 hortel pimenta Nutrition 0.000 claims description 11
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- -1 phytosterol Chemical compound 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000003094 microcapsule Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 240000002547 Rosa roxburghii Species 0.000 claims description 4
- 235000000640 Rosa roxburghii Nutrition 0.000 claims description 4
- 229930003944 flavone Natural products 0.000 claims description 4
- 235000011949 flavones Nutrition 0.000 claims description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 244000197580 Poria cocos Species 0.000 claims description 3
- 235000008599 Poria cocos Nutrition 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 241000208688 Eucommia Species 0.000 claims description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 2
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 2
- 241000219780 Pueraria Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- 235000010081 allicin Nutrition 0.000 claims description 2
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- 235000020243 first infant milk formula Nutrition 0.000 claims description 2
- 150000002213 flavones Chemical class 0.000 claims description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 235000012680 lutein Nutrition 0.000 claims description 2
- 229960005375 lutein Drugs 0.000 claims description 2
- 239000001656 lutein Substances 0.000 claims description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 2
- 235000012661 lycopene Nutrition 0.000 claims description 2
- 229960004999 lycopene Drugs 0.000 claims description 2
- 239000001751 lycopene Substances 0.000 claims description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000011812 mixed powder Substances 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 1
- 229920002498 Beta-glucan Polymers 0.000 claims 1
- 241000209140 Triticum Species 0.000 claims 1
- 241000489523 Veratrum Species 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 10
- 238000012545 processing Methods 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 5
- 235000003715 nutritional status Nutrition 0.000 abstract description 4
- 230000004202 respiratory function Effects 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 2
- 235000010469 Glycine max Nutrition 0.000 description 19
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 15
- 244000068988 Glycine max Species 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 229920002774 Maltodextrin Polymers 0.000 description 10
- 239000005913 Maltodextrin Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 229940035034 maltodextrin Drugs 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000005862 Whey Substances 0.000 description 9
- 102000007544 Whey Proteins Human genes 0.000 description 9
- 108010046377 Whey Proteins Proteins 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 229960003080 taurine Drugs 0.000 description 9
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 239000011648 beta-carotene Substances 0.000 description 7
- 235000013734 beta-carotene Nutrition 0.000 description 7
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 7
- 229960002747 betacarotene Drugs 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 235000019688 fish Nutrition 0.000 description 7
- 239000004006 olive oil Substances 0.000 description 7
- 235000008390 olive oil Nutrition 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 210000002345 respiratory system Anatomy 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 208000002720 Malnutrition Diseases 0.000 description 6
- 108010038807 Oligopeptides Proteins 0.000 description 6
- 102000015636 Oligopeptides Human genes 0.000 description 6
- 235000010489 acacia gum Nutrition 0.000 description 6
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003240 coconut oil Substances 0.000 description 6
- 235000019864 coconut oil Nutrition 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 230000001071 malnutrition Effects 0.000 description 6
- 235000000824 malnutrition Nutrition 0.000 description 6
- 208000015380 nutritional deficiency disease Diseases 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000003549 soybean oil Substances 0.000 description 6
- 235000012424 soybean oil Nutrition 0.000 description 6
- 235000008939 whole milk Nutrition 0.000 description 6
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 5
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 5
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 5
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 5
- 244000077995 Coix lacryma jobi Species 0.000 description 5
- 240000005717 Dioscorea alata Species 0.000 description 5
- 229920001503 Glucan Polymers 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 108010073771 Soybean Proteins Proteins 0.000 description 5
- 235000011453 Vigna umbellata Nutrition 0.000 description 5
- 240000001417 Vigna umbellata Species 0.000 description 5
- 230000000954 anitussive effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000015278 beef Nutrition 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000003022 colostrum Anatomy 0.000 description 5
- 235000021277 colostrum Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000004519 grease Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 235000019710 soybean protein Nutrition 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000011162 core material Substances 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- 239000011715 vitamin B12 Substances 0.000 description 4
- 239000011726 vitamin B6 Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 239000011647 vitamin D3 Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000206575 Chondrus crispus Species 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000001088 anti-asthma Effects 0.000 description 3
- 239000000924 antiasthmatic agent Substances 0.000 description 3
- 229940124584 antitussives Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000003019 respiratory muscle Anatomy 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 229920002752 Konjac Polymers 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000001989 choleretic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000003132 food thickener Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 101100504119 Arabidopsis thaliana GAMMACA2 gene Proteins 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000001759 Citrus maxima Nutrition 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 240000001740 Momordica dioica Species 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001300674 Plukenetia volubilis Species 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 241000287420 Pyrus x nivalis Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002430 glycogenolytic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000000864 hyperglycemic agent Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical group [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002729 menthone derivatives Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000001335 perilla frutescens leaf extract Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229930189407 platycodin Natural products 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to a kind of respiratory disease tailored version clinical nutrition formula, and it includes protein, fat, carbohydrate, dietary fiber, macroelement, trace element, liposoluble vitamin, water soluble vitamin, meals elite, integration of drinking and medicinal herbs composition, natural plants compound and new resource food;The invention further relates to the preparation method of above-mentioned clinical nutrition formula, powder is made in its each component in advance, and powder is made using alcohol extracting water extraction concentration, spray drying in integration of drinking and medicinal herbs composition, and vitamin and fat are handled by microencapsulation is made powder;Or powder is made to each component progress emulsifying homogeneous, spray drying by wet processing.Screening and proportioning by said components, nutrient formulation of the present invention provides the nutritional support of comprehensive abundance for respiratory disease patient, to improve passive protective physical fitness, certain effect is all achieved to nutritional status, respiratory function, the life quality for improving patient, more preferable condition is created for disease treatment.
Description
Technical field
The present invention relates to special medicine purposes formula food field, and in particular to a kind of respiratory disease tailored version is clinical
Nutrient formulation and preparation method thereof.
Background technology
Respiratory system is an open system, and environment and the occurrence and development of its disease have close relationship;In recent years
It was found that diet is also relevant with the generation of its disease, i.e., nutrient can adjust reaction of the human body to environmental poisonous substance.With atmosphere pollution
Aggravation, the inducement such as pollution, passive smoking of indoor dust and interior decoration, all easily trigger respiratory disease.Nutrition with
The relation of respiratory disease is mainly that nutrient can adjust reaction of the people to environmental poisonous substance, i.e. diet can suitably prevent environment not
The influence of sharp factor, conversely then increase to environment unfavorable factor for example anaphylactogen, tobacco smoke, infection, atmosphere pollution neurological susceptibility.
Vit C and Vit E and beta carotene are antioxidants, and antioxidant is anti-for first of oxygen radical
Line.In lungs, there is provided antioxidant defense effect in addition to endogenic enzyme and the anti-oxidant compounds of non-enzyme system, diet
In antioxidant particularly Vit C, Vit E and beta carotene it is also critically important.Epidemiological study shows that serum Vit C are low
Relevant with wheezing symptoms increase, its forced expiratory volume in one second (FEV1) of the diet intake less persons of Vit C is relatively low, and this influence
It is particularly evident in asthma patient.But how the effect of supplementing Vit C to asthma patient there is no final conclusion at present.Beta carotene is Vit
A precursor, it is deposited in tissue film, can remove O-2And peroxy radical can be directly acted on.Vitamin is to a certain extent
Can be to the injury of lungs caused by antioxidant.
ω -3 and ω -6 aliphatic acid is relevant with the formation of airway inflammation.The how unsaturated aliphatic acid of ω -3 (ω -3PUFA) stores up
Exist in cell membrane, played an important role in controlling inflammation, but it is easily substituted by ω -6PUFA, and the latter promotes the shape of inflammation
Into.It is now recognized that high intake ω -3PUFA can reduce the synthesis of inflammatory mediator leukotriene, but ω -3 fat is supplemented to asthma patient
Fat acid or fish oil but generate conflicting result.Subsequent people it has been observed that in diet ω -3 and ω -6 aliphatic acid ratio
Example is probably key factor in inflammatory metabolic Product formation, rather than absolute magnitude.Other ω -3PUFA can also suppress prostate
Plain E2 synthesis, thus reduce hypersensitive sensitization.
Sodium is extremely important at many aspects of regulation smooth muscle tension, therefore salt content high energy promotes airway disorders in diet
Formation, particularly airway hyper-reaction.Other sodium can also pass through the horizontal change of endogenous steroids and the release of catecholamine
Work.Magnesium also influences airway disorders, because it is relevant with the maintenance of cell membrane both sides current potential, and has bronchiectatic activity.
Magnesium can relax airway smooth muscle in vitro, can expand the air flue of asthma person in vivo, can suppress the transmission of cholinergic nerve muscle,
Stable loose and T- lymphocytes.
Malnutrition often occurs for COPD (COPD) patient, while with immunologic hypofunction.Nutrition
The bad muscular strength and endurance for reducing respiratory muscle, makes respiratory muscle fatigue easily occur, and maximal ventilatory volume and lung capacity decline.Ventilation is dynamic
Power reduces the secretion for making effectively cough reduce and can not exclude respiratory system;Malnutrition reduces ALB, it is difficult to maintains blood plasma
Colloid osmotic pressure, tissue space oedema, the water content of lung increase, and influence the diffusion of oxygen;Malnutrition makes immunoglobulin
(IgG) synthesis is reduced, and secretory IgA declines, and complement system activity reduces, the decline of neutrophil leucocyte bactericidal activity, blood leaching
Bar Leukopenia, body's immunity decline, and defence and the repair function of respiratory system tissue decline, and make infection in respiratory system difficult
To control or occur new infection;Malnutrition increases hormone in vivo level diacrisis, hyperglycemic factor, glucocorticoid etc.
Add, hepatic glycogenolytic, gluconeogenesis increase, organize the Use barriers to sugar, blood glucose rise, easily make Lung infection delay not
More.Malnutrition employs internal fat depot, and fat turns into the main source of energy, and Fatty Acids in Plasma increase, generation is largely
Ketoboidies, cause metabolic acidosis, aggravate the burden of respiratory system.Therefore malnutrition causes respiratory system structure and function different
Often, primary disease is aggravated, induces multiple complications, has a strong impact on the mobility and social function of patient, life quality reduces,
Prognosis is bad, even results in death.
Apply glucocorticoid treatment respiratory disease at present.Glucocorticoid is occurred by suppressing or promoting with inflammation
Develop the transcription of relevant some genes, suppress inflammatory process from many aspects.Glucocorticoid heavy dose short application use it is bad
Reaction has:(1) disorder of spirit and central nervous system, shows as anxious state of mind, even spiritedness is not normal;(2) Impaired Glucose Tolerance Treated
Even induced Diabetic;(3) water sodium storage is stayed;(4) disease of digestive tract and the symptom such as concurrent hemorrhage of gastrointestinal tract, peptic ulcer;(5)
Blood pressure increases;(6) glaucoma is caused;(7) diseases such as acute myopathy are induced;(8) heavy dose of too fast administration, it is accidental to have allergy anti-
Should.The adverse reaction of prolonged application has:(1) suppression of hypothalamic-pituitary-adrenal (HPA) axle makes corticotropin
(ACTH) secretion with cortin is reduced, and can cause iatrogenic adrenocortical insufficiency, severe patient may occur in which on kidney
Gland crisis;(2) the hyperfunction syndrome of class adrenal cortex function (cushing's syndrome);(3) there is antigrowth hormone, can
Influence children's bone growth and development;(4) old man and menopausal women osteoporosis and sclerotin can be caused to lower;(5) chronic myopathy;
(6) induce or aggravate infection;(7) wound healing is slow, atrophoderma.The effect of the doctor trained in Western medicine control course of disease is not very notable, in
Doctor is so in diagnosis and treatment based on an overall analysis of the illness and the patient's condition and the side's of sending medication, and because clinical experience and individual realize difference, numerous doctor's views are not quite similar, such as mulberry
Bai Pitang is applied to phlegm-heat accumulated in the lung type COPD, and the dynamics of resolving sputum and heat-clearing is not to same sufferer medication, in its side by different researchers
Together, it is and also different in the selection of medicinal material, resolving sputum Chinese medicine is such as directed to, someone is kind to use Poria cocos strengthening the spleen and reducing phlegm, and someone likes dry with rhizoma atractylodis
Humidifying phlegm, or both dual-purpose, etc., its single medicine dosage also has difference.The medication specification of the traditional Chinese medical science be difficult uniformly, it is empirical
By force.
Therefore, while development can provide the basal nutrient element needed for respiratory disease patient, and can is alleviated and controlled
The product for treating respiratory disease symptom has important value and wide market.
The content of the invention
A kind of the defects of it is an object of the invention to overcome in the prior art, there is provided the clinical battalion of respiratory disease tailored version
Formula and preparation method thereof is supported, it provides the nutritional support of comprehensive abundance for respiratory disease, and the nutrient formulation not only contains
Balanced three major nutrient, also containing multivitamin and mineral matter, there is provided high quality nutrition, strengthen immunologic function.Give
EN support, certain effect is all achieved to nutritional status, respiratory function, the life quality for improving patient, is disease
Treatment creates more preferable condition.Nutrient refers to provide energy to human body in food, participate in body composition and adjust physiology work(
The chemical composition of energy.Nutrition necessary to human body is known as protein, lipid, carbohydrate, mineral matter, vitamin, water, dietary fiber
Deng.
To achieve the above object, the present invention adopts the following technical scheme that:
First purpose of the present invention is to provide a kind of respiratory disease tailored version clinical nutrition formula, including such as the following group
Point and its parts by weight:18-24 parts protein, 22-28 parts fat, 35-42 parts carbohydrate, 4.5-7.5 parts meals are fine
Dimension, 0.7-1.5 parts macroelement, 0.01-0.04 parts trace element, 0.005-0.03 parts liposoluble vitamin, 0.1-0.2 part water
Soluble vitamin, 0.05-1 part meals elite, 0.05-2 part integration of drinking and medicinal herbs composition, 0.3-3 part natural plants compounds and
0.005-2 part new resource foods.
In order to further optimize above-mentioned clinical nutrition formula, the technical measures that the present invention is taken also include:
Preferably, the protein be selected from PURE WHEY, soybean protein isolate, hydrolysis Isin glue collagen, whole milk powder,
At least one of dried whole-egg, lactoferrin, bovine colostrum, amino acid, protein peptides;Wherein protein content is in whole milk powder
24wt%, fat content 34wt%, carbohydrate content 40wt%.
Wherein, the amino acid is selected from 1B-Pidolidone, Pidolidone, L-arginine, L-Trp, L- paddy
At least one of glutamine, taurine, Valine, ILE, L-Leu;The protein peptides are selected from soy oligosaccharides
At least one of peptide, wheat protein peptide, pupa albumen peptide, ocean fish oligopeptide, laughable peptide, amino peptide, ovalbumin peptide.
It is highly preferred that the protein includes PURE WHEY, soybean protein isolate, whole milk powder, dried whole-egg, colostrum
Powder, ocean fish oligopeptide, soybean oligopeptide, taurine.
Preferably, the fat includes saturated fatty acid, polyunsaturated fatty acid, monounsaturated fatty acids, OPO structures
At least one of fat, DHA, EPA, ARA, phosphatide, more specifically described fat include safflower seed oil, walnut oil, peanut oil,
Soybean oil, Ah's glycerine, olive oil, tea oil, oil and fat of sacha inchi, olive oil, coconut oil, perilla herb oil, deep sea fish oil, cupu oil, palm
Oil, butter, cream, lard, medium chain triglyceride, lecithin, Purple Perilla Seed Oil etc.;More preferably olive oil, soybean oil, coconut
Oil, perilla herb oil, medium chain triglyceride.
Preferably, the carbohydrate is included in fructose, rock sugar, lactose, maltodextrin, tapioca, resistant starch
At least two;More preferably maltodextrin, tapioca, rock sugar, lactose.
Preferably, in above-mentioned nutrient formulation, protein, fat, the productivity ratio of carbohydrate are 15~20:40~
50:35~40.More preferably 17:45:38.
Preferably, in above-mentioned nutrient formulation, medium chain triglyceride accounts for total lipid content and is higher than 40wt%, more preferably higher than
50wt%.
Preferably, the dietary fiber include inulin, konjaku flour, galactooligosaccharide, FOS, oligoisomaltose,
At least one of soybean polyoses, cyclodextrin, resistant dextrin, soybean fiber;It is highly preferred that the dietary fiber includes 3.5-
5.5 parts of water-soluble dietary fibers and 1~2 part of insoluble diedairy fiber, it includes soybean fiber.
Preferably, the macroelement is selected from calcium citrate, L-calcium lactate, calcium monohydrogen phosphate, K-IAO, sodium citrate
At least one of with magnesium gluconate.
Preferably, the trace element is selected from ferrous gluconate, KI, zinc gluconate, sodium selenite, glucose
At least one of sour copper, chromium sulfate, manganese gluconate and sodium molybdate.
Preferably, the liposoluble vitamin is selected from vitamin A, beta carotene, vitamin D3, vitamin E, vitamin
K1At least one of.
Preferably, the water soluble vitamin is selected from vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin
C, at least one of pantothenic acid, folic acid, nicotinic acid, choline, inositol, biotin.
Preferably, the meals elite is selected from cereal, beans, potato class, greengrocery, Homonemeae, nut-seed class, fishes and shrimps
At least one of class, poultry meat, fruits;The cereal is selected from rice meal, millet powder, black rice flour, coixlacrymajobi powder, corn
At least one of powder, wheat germ powder, oatmeal, buckwheat;The beans is selected from peameal, mung bean flour, black bean powder, red bean
At least one of powder, soy meal;The potato class is mainly made up of common yam rhizome powder;The Vegetable powder is selected from carrot meal, white radish powder, south
At least one of melon powder, spinach powder, tomato meal, broccoli powder, balsam pear powder;The Homonemeae be selected from mushroom powder, Kelp Powder and
At least one of white fungus powder;The nut-seed class is selected from least one of pumpkin seed powder and lotus nut starch;The fish and shrimp
Selected from least one of salmon powder and cod meal;The poultry meat is selected from chicken meal, powdered beef, pork liver powder and pig kidney powder
At least one of;The fruits in red date powder, longan powder, apple powder, cherry powder, citrus powder, pyrus nivalis powder at least
It is a kind of;More preferably coixlacrymajobi powder, red bean powder, common yam rhizome powder, powdered beef.
Preferably, the natural plants compound is selected from l-cn, Glucosamine, FOS, lutein, plant
At least one of sterol, lycopene, resveratrol, allicin;More preferably l-cn.
Preferably, the integration of drinking and medicinal herbs composition be selected from Poria cocos, lily, peppermint, radix glycyrrhizae, sealwort, Exocarpium Citri Rubrum, balloonflower root, Momordica grosvenori,
At least one of purple perilla.
It is highly preferred that the parts by weight of each component are as follows in the integration of drinking and medicinal herbs composition:0~1 part of lily, peppermint 0~1
Part, 0~1 part of radix glycyrrhizae, 0~1 part of sealwort, 0~1 part of Exocarpium Citri Rubrum, 0~1 part of balloonflower root, 0~1 part of Momordica grosvenori, 0~1 part of purple perilla.
Preferably, the new resource food is selected from first milk basic protein, γ-aminobutyric acid, chitosan oligosaccharide, eucommia Bark male flower, bamboo
Leaf flavones, CPP, avenabeta glucosan, Oligomeric manna sugar, stachyose, Rosa roxburghii, yeast beta-dextran, newborn mineral
At least one of salt, pueraria root powder, Rosa roxburghii, xylo-oligosaccharide.
It is highly preferred that the new resource food is avenabeta glucosan.
Second object of the present invention is to provide a kind of preparation of above-mentioned respiratory disease tailored version clinical nutrition formula
Method, it comprises the following steps:
Step 1) prepares fat powder, liposoluble vitamin powder and water soluble vitamin powder using micro-capsule embedding techniques
End;
Step 2) prepares integration of drinking and medicinal herbs component powders using crushing, alcohol extracting, water extraction, spray drying and sifting step;
Step 3) is smart by the protein of predetermined weight, carbohydrate, dietary fiber, macroelement, trace element, meals
China, natural plants compound and new resource food are prepared into the powder that particle diameter is 150~250 μm respectively, if desired
Above-mentioned raw materials can be carried out in advance baking processing;
Step 4) is by step 1)~3) sterilize after the powder for preparing is well mixed it is standby;
The mixed powder of step 4) is prepared into nutrient powder, nutrition emulsion, capsule by step 5) according to conventional technical means
At least one of agent, tablet, pill or oral liquid;
Wherein, step 1) -3) order can mutually change.
Finally, the present invention relates to a kind of product prepared by above-mentioned respiratory disease tailored version clinical nutrition formula, bag
Include nutrient powder, nutrition emulsion, capsule, tablet, pill, oral liquid etc..
In above-mentioned preparation method, wherein, the raw material of the integration of drinking and medicinal herbs composition is crushed, alcohol extracting concentration, water extraction are dense
Contracting, and concentrate is subjected to spray drying integration of drinking and medicinal herbs component powders are made;Wherein, the vitamin and fat are respectively by micro-
Encapsulated processing is prepared into vitamin powder and fat powder.
Preferably, the preparation process of the integration of drinking and medicinal herbs component powders is as follows:Using pulverizer to predetermined weight number
Raw material is crushed, and the raw material of crushing is placed in container, adds 3~5 times of 60~80% second that weight is raw material weight
Alcohol, soaked, extracted 2 times, merged alcohol extract and be concentrated into no alcohol taste;After the active compound dregs of a decoction fling to ethanol, weight is added as original
6~8 times of water of material weight is soaked, and is carried out 30~60min of decoction to soak, is filtered off except raw material, leaves and takes decoction
Liquid;Merge alcohol extract and decoction liquor after concentration, and it is spray-dried, it is same finally to prepare medicine food with 60~80 mesh sieves point
Derived components powder.
Preferably, what the microencapsulation of the vitamin was handled comprises the following steps that:1) using liposoluble vitamin as core
Material, from sodium carboxymethylcellulose, gelatin, carragheen, xanthans, Arabic gum, maltodextrin, lipoprotein, corn syrup, big
Beans protein isolate, whole-fat milk powder, dietary fiber, inulin, PURE WHEY, oligoisomaltose, soybean fiber, lactose, rock sugar
One or more in powder, emulsifying agent, stabilizer high-pressure homogeneous emulsification, are sprayed instantaneous dry, with 60~80 mesh sieves as wall material
Divide and prepare liposoluble vitamin powder;2) using water soluble vitamin as core, from sodium carboxymethylcellulose, gelatin, OK a karaoke club
Glue, xanthans, Arabic gum, maltodextrin, lipoprotein, corn syrup, soybean protein isolate, whole-fat milk powder, dietary fiber, chrysanthemum
One or more works in powder, PURE WHEY, oligoisomaltose, soybean fiber, lactose, candy sugar powder, emulsifying agent, stabilizer
For wall material, it is well mixed, sprays instantaneous dry, water soluble vitamin powder is prepared with 60~80 mesh sieves point.
Preferably, the specific implementation step of the fatty micro-capsule embedding techniques is as follows:By fat, emulsifying agent, wall material with
Water mixed dissolution prepares emulsion;After above-mentioned emulsion is stirred, emulsifying homogeneous processing is carried out, it is dry then to carry out spraying
Dry, screening prepares fat powder, and fat powder is compared with conventional grease, and its dispersiveness, water solubility, emulsibility, inoxidizability are all
Improve a lot;Wherein, the emulsifying agent be selected from fatty acid glyceride (glyceride), methyl glycol fatty acid ester (propylene glycol ester),
One in sorbitan aliphatic ester (sorbitan acid), sucrose fatty ester (sucrose ester), lecithin, monoglyceride, Tween 80
Kind is a variety of;The wall material is selected from sodium carboxymethylcellulose, gelatin, carragheen, xanthans, Arabic gum, maltodextrin, fat egg
In vain, corn syrup, soybean protein isolate, whole-fat milk powder, dietary fiber, inulin, PURE WHEY, oligoisomaltose, soybean
One or more in fiber, lactose, candy sugar powder, emulsifying agent, stabilizer.
The present invention also provides a kind of preparation method of above-mentioned respiratory disease tailored version clinical nutrition formula, and it is wet method
Technique, comprise the following steps:
Step 1) prepare the protein containing predetermined weight number, fat, carbohydrate, dietary fiber, macroelement,
Trace element, vitamin, integration of drinking and medicinal herbs composition, the raw material of natural plants compound and new resource food, in scheduled volume
In water, according to the physical behavior of raw material, added successively according to sequencing, be stirred while addition, raw material is made
Mixed emulsion;
The mixed emulsion temperature that step 1) obtains is maintained at 40-50 DEG C by step 2), and adjustment homogenization pressure makes it protect all the time
Hold between 10-18Mpa, emulsifying homogeneous is carried out to mixed emulsion, then placed emulsion in evaporator, with default technology
Parameter is concentrated, and is sterilized at 85-88 DEG C, obtains concentrate;
The concentrate that step 2) obtains is spray-dried by step 3), is crossed 60~80 mesh sieves, is prepared into powder;Using upper
State powder and be prepared at least one of nutrient powder, nutrition emulsion, capsule, tablet, pill or oral liquid.
In the present invention using include lily, peppermint, radix glycyrrhizae, sealwort, Exocarpium Citri Rubrum, balloonflower root, Momordica grosvenori, purple perilla integration of drinking and medicinal herbs into
Point, there is the effect of enhancing immunity of organisms, anti-virus ability after mentioned component compatibility synergy, can effectively improve respiratory system disease
Organism physiology, biochemistry and the immunologic function of patient.
Lily plays the role of significant phlegm-dispelling functions, calmness, antitoxic heart-soothing and sedative;Lily is rich in lymphatic temperament and vitamin, to skin
Skin cell metabolism is beneficial;Lily contains a variety of alkaloids, there is prevention effect to leukopenia, can hemocytes increasing, it is right
Cytopenia has therapeutic action after chemotherapy and radiation treatment;Lily can also promote and strengthen in vivo monocyte system and
Phagocytic function, improve the humoral immunity ability of body.
Peppermint has antiviral, sterilization, analgesia, itching-relieving action;Main component menthol has very strong in Herba Menthae Haplocalycis volatile oil
Choleretic effect;The anti-irritant effect of menthol causes tracheae to produce new secretion, and makes the mucus of stiff be easy to discharge, and dispels
Phlegm acts on;Menthol, menthones have inhibitory action to isolated rabbit intestines, and have digestion promoting function;Total flavonoid in peppermint has
Choleretic effect.
Licorice polysaccharide has antibechic, relievingd asthma, the pharmacological action such as lung preversation and respiratory pathogen, while also significantly inhibits
Adjust lung tissue intercellular adhesion molecule and produce protective effect;Licoflavone can effectively suppress the generation of lung inflammation medium,
With the pulmonary lesion such as pulmonary edema;There is good inhibitory action to NF-kB signal paths, the leather of effective prevention and treatment clinically
Infection of the Lan Shi negative bacteriums to lung.
Sealwort can make the activity increase of mouse liver superoxide dismutase, decline myocardium lipofuscin content;And mouse can be made
Erythrocyte membrane Na+, K+-ATP enzymatic activitys improve;Sealwort has hypotensive, hypoglycemic, reducing blood lipid, atherosclerosis, prolongs
The slow effect such as aging and antibacterial, Siberian solomonseal rhizome polysaccharide have Immunestimulatory effect.
Exocarpium Citri Rubrum has obvious correction disorders of lipid metabolism, reduces cholesterolemia, triglyceride and beta Lipoprotein, softens blood
Pipe, improve microcirculation, antiatherosclerosis, suppress platelet aggregation and reduce blood viscosity, be advantageous to blood circulation, accelerate
The effect of removing and the excretion of lipid residual particles (waste);Pummelo peel general flavone has obvious to chronic alcohol liver injury
Protective effect, general flavone have obvious oxidation resistant effect;Orange volatile oil has gentle stimulation to intestines and stomach, is advantageous to
The discharge of gastrointestinal pneumatosis, and the secretion of gastric juice can be promoted, help to digest;Volatile oil can also stimulate respiratory mucosa, make secretion
Thing increases, and sputum dilution, is advantageous to discharge;There is significant antibechic, eliminating the phlegm, anti-inflammatory, bacteriostasis simultaneously.
Balloonflower root may promote respiratory tract mucilage secretion, the platycodin contained by it to oral cavity, throat, mucous membrane it is direct
Stimulate, can increase to reflectivity bronchial mucosa hypersecretion, so that sputum dilutes, be easy to discharge, make so as to play eliminating the phlegm
With;Contained saponin(e has stronger antitussive effect in balloonflower root, also strengthens anti-inflammatory and immunization, its anti-inflammatory intensity with A Si
Forest form is seemingly;The water extract of balloonflower root can strengthen the phagocytic function of macrophage, strengthen the sterilizing power of neutrocyte, improve lysozyme
Activity, there is prevention effect to stress ulcer.
PEARLITOL 25C in Momordica grosvenori has an antitussive action, and Momordica grosvenori is tatanic to intestinal tube caused by acetylcholine or barium chloride
Contraction has antagonism, makes intestinal tube loose and spasmolysis;Also there is antagonism to intestinal tube relaxation caused by adrenaline, make intestinal tube
Recover spontaneous activity.
Purple perilla decoction has the refrigeration function of mitigation;There is promotion digestive juice secretion, promote the effect of gastrointestinal peristalsis;Branch can be reduced
Tracheae is secreted, and alleviates bronchial spasm;Its agent has inhibitory action to Escherichia coli, shigella dysenteriae, staphylococcus;Purple perilla can contract
Short blood clotting time, blood plasma recalcification time and APFI.
Compared with prior art, the invention has the advantages that:
(1) various nutrients are supplemented general equilibrium of the present invention, while are added with enhancing immunity of organisms, antiviral energy
The integration of drinking and medicinal herbs composition of the effect of power, antitussive and antiasthmatic, and effective effective substance is extracted using the method for water extraction alcohol extracting comprehensively, helping
While helping the malaise symptoms for improving respiratory disease patient, each internal organs ability of conditioning respiratory disease patient is played,
Strengthen the absorption of all kinds of nutriments.
(2) three big production capacity accountings are protein in nutrient formulation of the present invention:Fat:Carbohydrate=17:45:38.It is high
Fat low-carb is beneficial to PFT, blood gas index, the respiratory muscle strength for improving COPD patient, shortens Mechanical ventilation time;
Medium chain triglyceride accounts for total lipid content and is higher than 40wt%, and medium chain triglyceride can mitigate stomach and intestine burden, digest and assimilate more common
Fatty (long chain fatty acids LCT) easily, is properly added medium chain fatty acid, can be that COPD patient is quickly energized to meet it to energy
The demand of amount.
(3) 0.55 part of perilla herb oil of present invention addition, containing abundant polyunsaturated fatty acid, it increases the amount of n-3 aliphatic acid
It can reduce internal arachidonic acid (AA) ratio, EPA ratios increase in immunocyte membrane phospholipid, so as to promote immune tune
Section so that inflammation and dyscrasia are formed and reduced.The systemic inflammatory response that may occur for COPD patient, appropriate n-3 fat
Acid is effective anti-inflammatory, mitigates the symptom of COPD patient.
(4) present invention strengthens taurine, and taurine has inherent anti-inflammatory and antioxidation, and can prevent injury of lungs enters one
Step deteriorates and plays therapeutic action;Present invention addition addition broccoli elite, Caulis et Folium Brassicae capitatae have the work(of strengthening immune system
Can, and can protect or repair airway epithelial cell.
(5) present invention prepares vitamin using micro-capsule embedding techniques, and vitamin is embedded in wall material, can prevent dimension from giving birth to
Element is destroyed by macroelement, trace element, extends the holding time of vitamin;The present invention is prepared using micro-capsule embedding techniques
Powdered oil so that powdered oil has preferable mobility, is easy to be well mixed with other powdered components;And use micro-capsule bag
After burying technology, grease is embedded in wall material, so as to avoid the contact with air to strengthen inoxidizability, is protected so as to play
The maximum effect of strong type grease.
(6) raw material of respiratory disease tailored version clinical nutrition formula of the present invention is advance in preparation process
150~250 μm of powder is prepared into, this make it that, when preparing finished product, each nutrition composition can be well mixed, guarantor unit's volume
In each nutrition composition content it is essentially identical, while when preparing liquid type preparation, each nutrition composition can be fully dispersed and complete
Fully dissolved prevents occurring solid precipitation in liquid into solvent, the effect of finished product product has been effectively ensured.
The present invention is by the way that from rational basal nutrient element, using the proportioning of general equilibrium, while addition has enhancing machine
Body immunity, antiviral and anti-inflammatory power, the integration of drinking and medicinal herbs composition of antitussive and antiasthmatic, natural plants compound, new resource food etc.
Specific nutrient, and adjust its proportioning and carry out compatibility synergy with basal nutrient element, supplementing respiratory disease patient comprehensively must
The nutritional ingredient of palpus, and the nutrient formulation is easier to be absorbed by respiratory disease people digest, gives full play to its each component
Effect, passive protective physical fitness is improved, certain effect is all achieved to nutritional status, respiratory function, the life quality for improving patient,
More preferable condition is created for disease treatment.
Embodiment
The present invention provides a kind of respiratory disease tailored version clinical nutrition formula, it is characterised in that including following component
And its parts by weight:18-24 parts protein, 22-28 parts fat, 35-42 parts carbohydrate, 4.5-7.5 parts dietary fiber,
0.7-1.5 parts macroelement, 0.01-0.04 parts trace element, 0.005-0.03 parts liposoluble vitamin, 0.1-0.2 parts are water-soluble
Property vitamin, 0.05-1 part meals elite, 0.05-2 part integration of drinking and medicinal herbs composition, 0.3-3 part natural plants compounds and
0.005-2 part new resource foods.In the formula, dietary fiber is insoluble including 3.5-5.5 parts water-soluble dietary fiber, 1-2 parts
Dietary fiber;Protein, fat, the productivity ratio of carbohydrate are 17:45:38;Medium chain triglyceride accounts for total lipid content height
In 40wt%.
With reference to embodiment, the embodiment of the present invention is further described.Following examples are only used for more
Add and clearly demonstrate technical scheme, and can not be limited the scope of the invention with this.
Embodiment 1
Respiratory disease tailored version clinical nutrition formula of the present invention includes PURE WHEY 9.09g, soybean point
From albumen 7.27g, whole milk powder 21.8g, dried whole-egg 0.18g, bovine colostrum 0.1g, ocean fish oligopeptide 0.1g, soy oligosaccharides
Peptide 0.1g, taurine 0.12g;Olive oil 2.36g, soybean oil 3.82g, coconut oil 2.36g, perilla herb oil 0.55g, medium chain triglyceride
Three ester 9.73g;Maltodextrin 20.87g;Water-soluble dietary fiber 4.18g, soybean fiber 1.82g;Calcium in macroelement
0.514g, phosphorus 0.272g, potassium 0.106g, sodium 0.243g, magnesium 0.157g;Iron 0.011g, zinc 0.007g in trace element;Vitamin
A 0.0005g, beta carotene 0.017g, vitamin D30.000001g, vitamin E 0.009g;Vitamin B10.001g, dimension
Raw plain B20.001g, vitamin B60.001g, vitamin B120.0000017g, vitamin C 0.118g, pantothenic acid 0.003g,
Folic acid 0.00026g, nicotinic acid 0.0164g;Coixlacrymajobi powder 0.1g, red bean powder 0.1g, common yam rhizome powder 0.1g, powdered beef 0.1g, broccoli
Powder 0.1g, lily 0.1g, peppermint 0.1g, radix glycyrrhizae 0.1g, sealwort 0.1g, Exocarpium Citri Rubrum 0.1g, balloonflower root 0.1g, Momordica grosvenori 0.1g, purple perilla
0.1g, l-cn 0.636g, avenabeta glucosan 0.018g.
Embodiment 2
Respiratory disease tailored version clinical nutrition formula of the present invention includes PURE WHEY 9.09g, soybean point
From albumen 7.27g, whole milk powder 21.8g, dried whole-egg 0.18g, bovine colostrum 0.1g, ocean fish oligopeptide 0.1g, soy oligosaccharides
Peptide 0.1g, taurine 0.12g;Olive oil 1.36g, soybean oil 2.82g, coconut oil 1.36g, perilla herb oil 0.55g, medium chain triglyceride
Three ester 6.73g;Maltodextrin 26.87g;Water-soluble dietary fiber 4.18g, soybean fiber 1.82g;Calcium in macroelement
0.514g, phosphorus 0.272g, potassium 0.106g, sodium 0.243g, magnesium 0.157g;Iron 0.011g, zinc 0.007g in trace element;Vitamin
A 0.0005g, beta carotene 0.017g, vitamin D30.000001g, vitamin E 0.009g;Vitamin B10.001g, dimension
Raw plain B20.001g, vitamin B60.001g, vitamin B120.0000017g, vitamin C 0.118g, pantothenic acid 0.003g,
Folic acid 0.00026g, nicotinic acid 0.0164g;Coixlacrymajobi powder 0.1g, red bean powder 0.1g, common yam rhizome powder 0.1g, powdered beef 0.1g, broccoli
Powder 0.1g, lily 0.1g, peppermint 0.1g, radix glycyrrhizae 0.1g, sealwort 0.1g, Exocarpium Citri Rubrum 0.1g, balloonflower root 0.1g, Momordica grosvenori 0.1g, purple perilla
0.1g, l-cn 0.636g, avenabeta glucosan 0.018g.
Embodiment 3
Respiratory disease tailored version clinical nutrition formula of the present invention includes PURE WHEY 9.09g, soybean point
From albumen 7.27g, whole milk powder 21.8g, dried whole-egg 0.18g, bovine colostrum 0.1g, ocean fish oligopeptide 0.1g, soy oligosaccharides
Peptide 0.1g, taurine 0.12g;Olive oil 1.36g, soybean oil 2.82g, coconut oil 1.36g, perilla herb oil 0.55g, medium chain triglyceride
Three ester 6.73g;Maltodextrin 26.87g;Water-soluble dietary fiber 4.18g, soybean fiber 1.82g;Calcium in macroelement
0.514g, phosphorus 0.272g, potassium 0.106g, sodium 0.243g, magnesium 0.157g;Iron 0.011g, zinc 0.007g in trace element;Vitamin
A 0.0005g, beta carotene 0.017g, vitamin D30.000001g, vitamin E 0.009g;Vitamin B10.001g, dimension
Raw plain B20.001g, vitamin B60.001g, vitamin B120.0000017g, vitamin C 0.118g, pantothenic acid 0.003g,
Folic acid 0.00026g, nicotinic acid 0.0164g;Coixlacrymajobi powder 0.1g, red bean powder 0.1g, common yam rhizome powder 0.1g, powdered beef 0.1g, broccoli
Powder 0.1g, lily 0.01g, peppermint 0.01g, radix glycyrrhizae 0.01g, sealwort 0.01g, Exocarpium Citri Rubrum 0.01g, balloonflower root 0.01g, Momordica grosvenori
0.01g, purple perilla 0.01g, l-cn 0.636g, avenabeta glucosan 0.018g.
Embodiment 4
A kind of preparation method of the special clinical nutrition formula of respiratory disease as described in 1~embodiment of embodiment 3 is such as
Under:
1) powdered oil (powder fat) is prepared:
A) the wall material aqueous solution is prepared:Take 8 grams of maltodextrin, 4 grams of soybean protein isolate, 11 grams of whole-fat milk powder, dietary fiber 2
Gram (resistant dextrin), 0.5 gram of inulin, 5 grams of PURE WHEY, 0.5 gram of oligoisomaltose, 1 gram of soybean fiber, Arabic gum
0.2 gram, 0.5 gram of lactose, 2 grams of candy sugar powder, 50 milliliters of water stirs and (has ready conditions and heat while stirring to 60 DEG C, kept for 30 points
Room temperature is cooled to after clock).
B) 0.1 gram (total solid concentration is 0.2%) is taken uniformly to be dissolved in (olive oil in 17.66 milliliters of greases monoglyceride
2.22 milliliters, 3.59 milliliters of soybean oil, 2.22 milliliters of coconut oil, 0.52 milliliter of perilla herb oil, 9.13 milliliters of medium chain triglyceride).
C) 0.1 gram (total solid concentration is 0.2%) is taken uniformly to be dissolved in the wall material aqueous solution Tween 80.
D) the wall material aqueous solution of the mixed plant grease and addition Over emulsfication agent Tween 80 of Over emulsfication agent monoglyceride will be added
It is sufficiently mixed.
E) after addition stabilizer agar takes 0.1 gram (total solid concentration is 0.2%) to enter mixed solution, it is settled to water
200 milliliters (total solid concentration be 25%), disperse 2 minutes at a high speed under 20000r/min.
F) homogenization pressure is 25MPa, homogeneous 3 times (every time 5 minutes), homogeneous emulsion is made.
G) obtained emulsion is spray-dried, EAT is 195 DEG C, and leaving air temp is 80 DEG C.Collect powder
Grease (powder fat).
2) integration of drinking and medicinal herbs component powders are prepared:The raw material of predetermined weight number is crushed using pulverizer, will be crushed
Raw material be placed in container, the raw material of predetermined weight number is crushed using pulverizer, the raw material of crushing is placed in container
In, 3~5 times of 60~80% ethanol that weight is raw material weight are added, is soaked, extracted 2 times, merges alcohol extract and concentrates
To without alcohol taste;After the active compound dregs of a decoction fling to ethanol, add weight and soaked for 6~8 times of water of raw material weight, soak is entered
Row decocts 30~60min, filters off except raw material, leaves and takes decoction liquor;Merge alcohol extract and decoction liquor after concentration, and it is carried out
Spray drying, finally prepare integration of drinking and medicinal herbs component powders with 60~80 mesh sieves point;
3) vitamin powder is prepared:Using the liposoluble vitamin of predetermined weight number as core, from oligomeric different malt
Sugar is used as wall material, carries out 2 emulsifying homogeneous processing under high pressure, the emulsifying homogeneous time is 10~15min, then carries out spraying wink
When dry, point prepare liposoluble vitamin powder with 60~80 mesh sieves;Using the water soluble vitamin of predetermined weight number as core
Material, from maltodextrin, oligoisomaltose as wall material, it is well mixed, sprays instantaneous dry, prepared with 60~80 mesh sieves point
Water soluble vitamin powder;
4) by the protein of predetermined weight, carbohydrate, dietary fiber, macroelement, trace element, meals elite,
Natural plants compound and new resource food are prepared into the powder that particle diameter is 150~250 μm respectively;(step 1) -4) order
Can mutually it change)
5) by step 1) -4) prepare powder in the similar devices such as mixer be well mixed after sterilize it is standby;
6) according to conventional technical means by step 5) sterilize after powder be prepared into nutrient powder, nutrition emulsion, capsule,
At least one of tablet, pill or oral liquid.
In step 6), optionally increase appropriate food thickening agent, food additives and related formulation auxiliary material.
The food thickening agent is in guar gum, xanthans, locust bean gum, konjac glucomannan, pectin, carragheen, agar, gelatin, Arabic gum
At least one, the food additives are Aspartame, flavoring essence spices, at least one of brown sugar;More preferably OK a karaoke club
Glue, Arabic gum, guar gum, Aspartame, flavoring essence spices.
Aforesaid operations step is both needed to carry out under the protection of inert gas, such as nitrogen, argon gas, helium etc., to prevent from producing
The danger of green powder blast.
According to described with the classifications such as powdery, graininess, capsule shape, tablet shape, beverage can be prepared into.
Embodiment 5
1) influence of nutrient formulation preparation prepared by the present invention to normal mouse weight;
The nutrient powder for taking the embodiment of the present invention 1~3 to prepare is tested, while sets comparative example 1, comparative example 2 and blank pair
According to group, comparative example 1 is right using the nutrient powder for not adding taurine and medium chain triglyceride preparation in the nutrient formulation of embodiment 2
Ratio 2 is using the nutrient powder for not adding the preparation of integration of drinking and medicinal herbs composition in the nutrient formulation of embodiment 2, blank control group gavage physiology
Salt solution.
SPF level BALB/C mices, male and female half and half, body weight 25-30g, every group 10.Filled daily according to 0.3g/10g dosage
Stomach mouse, continuous 30 days.Fed to single cage during mouse stomach, determine it daily and take in appetite, claim 1 body weight within every 3 days, finally
Each group increased weight is calculated, is shown in Table 1.15
Influence of the respiratory disease tailored version clinical nutrition formula of table 1 to mouse weight
Group | First body weight/g | Whole body weight/g | Weightening/g |
Embodiment 1 | 25.2 | 42.3 | 17.1 |
Embodiment 2 | 26.8 | 43.5 | 16.7 |
Embodiment 3 | 27.3 | 45.2 | 17.9 |
Comparative example 1 | 29.7 | 45.5 | 15.8 |
Comparative example 2 | 28.5 | 43.6 | 15.1 |
Control group | 25.9 | 39.4 | 13.5 |
Through toxotest, rat its body weight, food-intake, liver function, renal function, blood, routine urinalysis and each histopathology are examined
Look into discovery without exception.
From the above results, the nutrient formulation has no and significantly affected that it can maintain mouse to mouse weight growth
Normal physiological function, harmful effect is not produced to the normal growth of mouse, that is, shows that nutrient formulation of the present invention has
Maintain material needed for mouse normal growth.
2) therapeutic effect of nutrient formulation preparation prepared by the present invention to respiratory disease patient;
The nutrient powder prepared using the embodiment of the present invention 1~3 is tested, while sets comparative example 1, comparative example 2, comparative example
1 using nutrient powder prepared by taurine and medium chain triglyceride is not added in the nutrient formulation of embodiment 2, comparative example 2 is using real
Apply the nutrient powder for not adding the preparation of integration of drinking and medicinal herbs composition in the nutrient formulation of example 2.
Selection respiratory disease patient (including chronic cough of deficiency lung, asthma, pulmonary tuberculosis etc.) 300,40~60 years old age,
Above-mentioned patient is randomly divided into 5 groups, every group of 60 people, treated 2~3 months, embodiment 1~3 and comparative example 1~2 take above-mentioned system
Standby nutrient powder, each 15g 1 day 3 times, take after postprandial half an hour, refuse to obey during experiment and treat respiratory system disease with any
The medicine of disease.
Curative effect situation criterion:Recovery from illness:Subjective symptoms and clinical sign disappear, and abnormal physico-chemical examination index is recovered just
Often;It is effective:Subjective symptoms and clinical sign largely disappear, and abnormal physico-chemical examination index is close to normally;Effectively:Subjective symptoms and
Clinical sign partial disappearance, abnormal physico-chemical examination index make moderate progress;It is invalid:Subjective symptoms is not improved or aggravated, clinical
Sign is not improved, and abnormal physico-chemical examination index is without improvement.
Its experimental result such as following table:
Group | Case number | Healing number | Effective number | Efficiently individual quantity | Invalid number | It is efficient |
Embodiment 1 | 60 | 32 | 18 | 6 | 4 | 93.3% |
Embodiment 2 | 60 | 29 | 22 | 4 | 5 | 91.7% |
Embodiment 3 | 60 | 34 | 15 | 8 | 3 | 95.0% |
Comparative example 1 | 60 | 28 | 18 | 6 | 8 | 86.7% |
Comparative example 2 | 60 | 25 | 16 | 10 | 9 | 85.0% |
As seen from the above table, 1~2 pair of embodiment 1~3, comparative example treatment respiratory disease are effective in cure, but present invention system
The effect of standby nutrient formulation, is better than comparative example 1~2, and this shows that each component has collaboration in nutrient formulation prepared by the present invention
Effect.
From above-described embodiment, various components are mutual in the special clinical nutrition formula of respiratory disease of the present invention
It is engaged, reasonable, comprehensive nutritional support is provided for respiratory disease patient, to improve the body of respiratory disease patient
State, at the same add with strengthen immunity of organisms, antiviral and anti-inflammatory power, antitussive and antiasthmatic integration of drinking and medicinal herbs composition,
Natural plants compound, new resource food, passive protective physical fitness is improved, nutritional status, respiratory function, existence matter to improving patient
Amount all achieves certain effect, and more preferable condition is created for disease treatment.
The specific embodiment of the present invention is described in detail above, but it is only used as example, and the present invention is not intended to limit
In particular embodiments described above.To those skilled in the art, it is any to the equivalent modifications that carry out of the present invention and to replace
In generation, is also all among scope of the invention.Therefore, the impartial conversion made without departing from the spirit and scope of the invention and repair
Change, all should be contained within the scope of the invention.
Claims (9)
1. a kind of respiratory disease tailored version clinical nutrition formula, it is characterised in that including following component and its parts by weight:
18-24 parts protein, 22-28 parts fat, 35-42 parts carbohydrate, 4.5-7.5 parts dietary fiber, 0.7-1.5 parts constant member
Element, 0.01-0.04 parts trace element, 0.005-0.03 parts liposoluble vitamin, 0.1-0.2 parts water soluble vitamin, 0.05-1
Part meals elite, 0.05-2 part integration of drinking and medicinal herbs composition, 0.3-3 part natural plants compounds and 0.005-2 part new resource foods;
Wherein, the integration of drinking and medicinal herbs composition is in Poria cocos, lily, peppermint, radix glycyrrhizae, sealwort, Exocarpium Citri Rubrum, balloonflower root, Momordica grosvenori, purple perilla
At least one;
Wherein, the dietary fiber includes 3.5-5.5 parts water-soluble dietary fiber, 1-2 part insoluble diedairy fibers.
A kind of 2. respiratory disease tailored version clinical nutrition formula according to claim 1, it is characterised in that the medicine
Food is lily, peppermint, radix glycyrrhizae, sealwort, Exocarpium Citri Rubrum, balloonflower root, Momordica grosvenori, purple perilla with derived components.
A kind of 3. respiratory disease tailored version clinical nutrition formula according to claim 2, it is characterised in that the medicine
Food is as follows with the parts by weight of derived components:0~1 part of lily, 0~1 part of peppermint, 0~1 part of radix glycyrrhizae, 0~1 part of sealwort, Exocarpium Citri Rubrum 0~1
Part, 0~1 part of balloonflower root, 0~1 part of Momordica grosvenori, 0~1 part of purple perilla.
A kind of 4. respiratory disease tailored version clinical nutrition formula according to claim 1, it is characterised in that the battalion
Support in formula, protein, fat, the productivity ratio of carbohydrate are 15~20:40~50:35~40.More preferably 17:45:
38。
A kind of 5. respiratory disease tailored version clinical nutrition formula according to claim 1, it is characterised in that the battalion
Support in formula, medium chain triglyceride accounts for total lipid content and is higher than 40wt%.
A kind of 6. respiratory disease tailored version clinical nutrition formula according to claim 1, it is characterised in that the day
Right plant compound is selected from l-cn, Glucosamine, FOS, lutein, phytosterol, lycopene, white black false hellebore
At least one of alcohol, allicin.
7. a kind of respiratory disease tailored version clinical nutrition formula according to claim 1, it is characterised in that described new
Resource food is selected from first milk basic protein, γ-aminobutyric acid, chitosan oligosaccharide, eucommia Bark male flower, bamboo-leaves flavones, CPP, swallow
Wheat beta glucan, Oligomeric manna sugar, stachyose, Rosa roxburghii, yeast beta-dextran, newborn mineral salt, pueraria root powder, Rosa roxburghii, xylo-oligosaccharide
At least one of.
It is 8. a kind of such as the preparation side of respiratory disease tailored version clinical nutrition formula according to any one of claims 1 to 7
Method, it is characterised in that comprise the following steps:
The fat, liposoluble vitamin, water soluble vitamin of step (1) predetermined weight are respectively adopted micro-capsule embedding techniques and prepared simultaneously
Cross 60~80 mesh sieves and powder is made;
The integration of drinking and medicinal herbs composition of step (2) predetermined weight is made up of crushing, alcohol extracting, water extraction, spray drying and 60-80 mesh sieves excessively
Powder;
Remaining component of step (3) predetermined weight is prepared into the powder that particle diameter is 150~250 μm respectively;
The powder that step (4) prepares step (1)~(3) is sterilized standby after being well mixed;
Direct-edible pharmaceutical formulation is made in step (4) mixed powder by step (5);
Wherein, the order of step (1)~(3) can be changed mutually;The pharmaceutical formulation include nutrient powder, nutrition emulsion, capsule,
Tablet, pill, oral liquid.
9. according to the preparation method of respiratory disease tailored version clinical nutrition formula according to any one of claims 1 to 7,
It is characterised in that it includes following steps:
Step 1) prepares the protein containing predetermined weight number and amino acid, nucleotides, fat, carbohydrate, meals are fine
Dimension, macroelement, trace element, vitamin, integration of drinking and medicinal herbs composition, the raw material of natural plants compound and new resource food
Powder, in the water of scheduled volume, according to the physical behavior of raw material, add according to sequencing, enter while addition successively
Row stirring, the mixed emulsion of raw material is made;
The mixed emulsion that step 2) obtains step 1) carries out emulsifying homogeneous, concentrating sterilizing, obtains concentrate;
The concentrate that step 2) obtains is spray-dried by step 3), sieving, is prepared into powder, and above-mentioned powder is prepared into
At least one of nutrient powder, nutrition emulsion, capsule, tablet, pill or oral liquid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710731367.4A CN107440103A (en) | 2017-08-23 | 2017-08-23 | A kind of respiratory disease tailored version clinical nutrition formula and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710731367.4A CN107440103A (en) | 2017-08-23 | 2017-08-23 | A kind of respiratory disease tailored version clinical nutrition formula and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107440103A true CN107440103A (en) | 2017-12-08 |
Family
ID=60493911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710731367.4A Pending CN107440103A (en) | 2017-08-23 | 2017-08-23 | A kind of respiratory disease tailored version clinical nutrition formula and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107440103A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108013452A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | A kind of puerperal abdominal flatulence gas tailored version clinical nutrition formula and preparation method thereof |
CN108618129A (en) * | 2018-05-10 | 2018-10-09 | 上海奥医生物医药科技有限公司 | Sarcopenia tailored version clinical nutrition formula and preparation method thereof |
CN108651988A (en) * | 2018-05-10 | 2018-10-16 | 上海奥医生物医药科技有限公司 | Nephrosis dialysis tailored version clinical nutrition formula and preparation method thereof |
CN108669540A (en) * | 2018-05-10 | 2018-10-19 | 上海奥医生物医药科技有限公司 | Cerebral apoplexy tailored version clinical nutrition formula and preparation method thereof |
CN108703364A (en) * | 2018-05-10 | 2018-10-26 | 上海奥医生物医药科技有限公司 | Treating fatty acid metabolism tailored version clinical nutrition formula and preparation method thereof |
CN109497514A (en) * | 2018-10-23 | 2019-03-22 | 上海奥医生物医药科技有限公司 | AIDS tailored version clinical nutrition formula and preparation method thereof |
CN109601878A (en) * | 2018-08-07 | 2019-04-12 | 丽睿客信息科技(北京)有限公司 | For protecting the nutraceutical of injury of lungs |
CN113712197A (en) * | 2021-08-30 | 2021-11-30 | 健康元药业集团股份有限公司 | Nutritional composition for respiratory diseases and preparation method thereof |
CN114886112A (en) * | 2022-05-13 | 2022-08-12 | 云南西草资源开发有限公司 | Special medical formula food for respiratory system diseases |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106666728A (en) * | 2016-12-23 | 2017-05-17 | 上海奥医生物医药科技有限公司 | Special clinical nutrient composition for gestational diabetes and preparation method of nutrient composition |
CN106858620A (en) * | 2017-03-29 | 2017-06-20 | 上海奥医生物医药科技有限公司 | A kind of anaemia tailored version clinical nutrition formula and preparation method thereof |
CN106942748A (en) * | 2017-03-29 | 2017-07-14 | 上海奥医生物医药科技有限公司 | A kind of female acyesis tailored version clinical nutrition formula and preparation method thereof |
CN106962912A (en) * | 2017-03-29 | 2017-07-21 | 上海奥医生物医药科技有限公司 | A kind of hepatopathy tailored version clinical nutrition formula and preparation method thereof |
CN106983136A (en) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | A kind of puerperium conditioning tailored version clinical nutrition formula and preparation method thereof |
CN106983151A (en) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | A kind of inflammatory bowel disease tailored version clinical nutrition formula and preparation method thereof |
-
2017
- 2017-08-23 CN CN201710731367.4A patent/CN107440103A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106666728A (en) * | 2016-12-23 | 2017-05-17 | 上海奥医生物医药科技有限公司 | Special clinical nutrient composition for gestational diabetes and preparation method of nutrient composition |
CN106858620A (en) * | 2017-03-29 | 2017-06-20 | 上海奥医生物医药科技有限公司 | A kind of anaemia tailored version clinical nutrition formula and preparation method thereof |
CN106942748A (en) * | 2017-03-29 | 2017-07-14 | 上海奥医生物医药科技有限公司 | A kind of female acyesis tailored version clinical nutrition formula and preparation method thereof |
CN106962912A (en) * | 2017-03-29 | 2017-07-21 | 上海奥医生物医药科技有限公司 | A kind of hepatopathy tailored version clinical nutrition formula and preparation method thereof |
CN106983136A (en) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | A kind of puerperium conditioning tailored version clinical nutrition formula and preparation method thereof |
CN106983151A (en) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | A kind of inflammatory bowel disease tailored version clinical nutrition formula and preparation method thereof |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108013452A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | A kind of puerperal abdominal flatulence gas tailored version clinical nutrition formula and preparation method thereof |
CN108618129A (en) * | 2018-05-10 | 2018-10-09 | 上海奥医生物医药科技有限公司 | Sarcopenia tailored version clinical nutrition formula and preparation method thereof |
CN108651988A (en) * | 2018-05-10 | 2018-10-16 | 上海奥医生物医药科技有限公司 | Nephrosis dialysis tailored version clinical nutrition formula and preparation method thereof |
CN108669540A (en) * | 2018-05-10 | 2018-10-19 | 上海奥医生物医药科技有限公司 | Cerebral apoplexy tailored version clinical nutrition formula and preparation method thereof |
CN108703364A (en) * | 2018-05-10 | 2018-10-26 | 上海奥医生物医药科技有限公司 | Treating fatty acid metabolism tailored version clinical nutrition formula and preparation method thereof |
CN109601878A (en) * | 2018-08-07 | 2019-04-12 | 丽睿客信息科技(北京)有限公司 | For protecting the nutraceutical of injury of lungs |
CN109497514A (en) * | 2018-10-23 | 2019-03-22 | 上海奥医生物医药科技有限公司 | AIDS tailored version clinical nutrition formula and preparation method thereof |
CN113712197A (en) * | 2021-08-30 | 2021-11-30 | 健康元药业集团股份有限公司 | Nutritional composition for respiratory diseases and preparation method thereof |
CN114886112A (en) * | 2022-05-13 | 2022-08-12 | 云南西草资源开发有限公司 | Special medical formula food for respiratory system diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107440103A (en) | A kind of respiratory disease tailored version clinical nutrition formula and preparation method thereof | |
CN106983136A (en) | A kind of puerperium conditioning tailored version clinical nutrition formula and preparation method thereof | |
CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
CN106858620A (en) | A kind of anaemia tailored version clinical nutrition formula and preparation method thereof | |
CN108013454A (en) | Gynaecological imflammation tailored version clinical nutrition formula and preparation method thereof | |
CN106072573A (en) | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible | |
CN106962912A (en) | A kind of hepatopathy tailored version clinical nutrition formula and preparation method thereof | |
CN109123643A (en) | A kind of preparation method of cereal generation meal ball | |
CN107440120A (en) | A kind of children's monophagia and anorexia tailored version clinical nutrition formula particular about food and preparation method thereof | |
CN112203531A (en) | Complete pea protein based nutritional composition | |
CN107927754A (en) | Tailored version clinical nutrition formula and preparation method thereof is energized during one kind production | |
CN108077911A (en) | A kind of epileptic's tailored version clinical nutrition formula and preparation method thereof | |
CN107373672A (en) | A kind of irregular menstruation women tailored version clinical nutrition formula and preparation method thereof | |
CN108703365A (en) | Protein allergy tailored version clinical nutrition formula and preparation method thereof | |
CN107440121A (en) | A kind of Single Obesity tailored version clinical nutrition formula and preparation method thereof | |
CN107616490A (en) | A kind of postoperative tailored version clinical nutrition formula of children and preparation method thereof | |
CN106858595A (en) | One kind burn tailored version clinical nutrition formula and preparation method thereof | |
CN101816425B (en) | Powder mixture of whole American ginseng/giant salamander and preparation method thereof | |
CN110432482A (en) | A kind of infant allergic dermatitis tailored version clinical nutrition formula and preparation method thereof | |
CN110074397A (en) | A kind of upgrowth and development of children tailored version clinical nutrition formula and preparation method thereof | |
CN106578093A (en) | Wound, infection, operation and other stress state special-purpose clinical nutrition formula and preparation method thereof | |
CN108013452A (en) | A kind of puerperal abdominal flatulence gas tailored version clinical nutrition formula and preparation method thereof | |
CN108887564A (en) | A kind of selenoprotein coarse cereal powder formula and preparation method thereof | |
CN107441217B (en) | Oral emulsion rich in alpha-linolenic acid and preparation method thereof | |
CN107440102A (en) | A kind of climacteric women tailored version clinical nutrition formula and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171208 |
|
RJ01 | Rejection of invention patent application after publication |